Dr. Pedro Berraondo

Clínica Universidad de Navarra

See Curriculum
Dr. Pedro Berraondo obtuvo la licenciatura en Farmacia en la Universidad de Navarra en 1999. En 2004 defendió la tesis doctoral en la misma universidad dentro del programa “Diseño, síntesis y evaluación de medicamentos”. Su principal proyecto fue la producción y la evaluación de un virus adenoasociado que expresa interferón alfa para el tratamiento de la hepatitis crónica en el modelo de la marmota. Dr. Berraondo realizó una estancia postdoctoral en el Instituto Pasteur de Paris (Francia) bajo la supervisión de la Dra. Claude Leclerc, donde trabajó en inmunoterapia tumoral dentro del proyecto europeo THERAVAC. En Febrero 2007, se unió a la división de Terapia Génica y Hepatología del Centro de Investigación Médica Aplicada (CIMA). Su investigación se centra en la inmunoterapia del cáncer mediante proteínas y péptidos estabilizados.

Dr. David F.Mc Dermott

Harvard Cancer Center. Boston. EE.UU

See Curriculum
Not available yet

Dr. Joaquim Bellmunt

IMIM-Parc de Salut Mar. Barcelona

See Curriculum
El Dr. Bellmunt combina la dirección del Instituto Oncológico Equipo Dr.Bellmunt – Hospital Universitari Dexeus Grupo Quirón con la dirección de la Bladder Cancer Center del Dana Farber Cancer Institute (DFCI) de Harvard, Boston (EUA). Asimismo, sigue vinculado al Servicio de Oncologia del Hospital del Mar y a la European Association for Research and Treatment of Cancer(EORTC).
El Dr. Joaquim Bellmunt se licenció en Medicina y Cirugía en la Universidad Autónoma de Barcelona en 1982 y se doctoró cum laude en 1989, en la misma universidad. Completó su formación obteniendo el Certificado Europeo en Oncología Médica en Londres en 1989 y con estancias en el Servicio de Inmunología Clínica, División de Oncología Médica y Departamento de Inmunotopatología en el Memorial Sloan-Kettering Cancer Center de Nueva York en 1987 y 1989. Tras completar la residencia, se unió al Servicio de Oncología Médica del Hospital Vall d’Hebron como responsable de la Unidad Urooncológica. En enero de 2006 fue nombrado Jefe de la Sección de Tumores Sólidos del Servicio de Oncología Médica del Hospital del Mar en Barcelona. Desde verano del 2008 y fruto de su colaboración con el Dana Farber Cancer Institute (DFCI), hasta finales 2012 fue Visiting Professor de la Universidad de Harvard, Boston, MA. Desde Marzo de 2013 fue nombrado director del Bladder Cancer Center del DFCI, Harvard, Boston (EUA) y Profesor Asociado de Harvard.
Fue presidente del Comité de Cáncer de Vejiga Avanzado en la Organización Europea para la Investigación y el Tratamiento del Cáncer (EORTC) y consultor del Grupo Génito-Urinario (EORTC-GU) desde el año 2000. Es co-fundador y ha sido presidente del Grupo Español de Tratamiento de Tumores Génito-Urinarios (SOGUG). Es asimismo Profesor de Medicina en la Universitat Pompeu Fabra de Barcelona y asesor editorial de las publicaciones Journal of Clinical Oncology, Annals of Oncology, European Urology, European Journal of Cancer, British Journal of Urology Int. y Journal of Urology, entre otras. El Dr. Joaquim Bellmunt ha publicado más de 350 artículos arbitrados y más de 340 comunicaciones en congresos y capítulos de libro.

Sus áreas de interés en investigación son la oncología clínica génito-urinaria, los fármacos dirigidos a nuevas dianas terapéuticas y la investigación clínica precoz y translacional en el ámbito de la inmunoterapia y los receptores de factores de crecimiento y la angiogénesis, entre otros, como objetivos en la terapia del cáncer. Dirige ensayos internacionales multicéntricos de nuevos fármacos inmunoterápicos en el tratamiento del cáncer de próstata, riñón y vejiga. Ha coordinado el Integrupo de estudio en cáncer transicional avanzado (EORTC 30987). Trabaja en el desarrollo clínico de varios agentes y combinaciones nuevas y es miembro del advisory board de numerosas terapias en la lucha contra el cáncer. Es miembro de la Sociedad Americana para la Investigación del Cáncer (AACR), de la Asociación Americana de Oncología Clínica (ASCO), de la Asociación Europea de Oncología Médica (ESMO) y de la Sociedad Española de Oncología Médica (SEOM). Participa como asesor experto en la elaboración y desarrollo de las Oncoguies del CatSalut de la Generalitat de Catalunya.

Forma parte del Comité Científico del Congreso Americano de la American Society of Clinical Oncology –Genitourinary (ASCO GU) donde realiza conferencias y es Faculty Memeber.

Dr. Josep Mª Piulats

Institut Català d’Oncologia,
Barcelona

See Curriculum
Not available yet

Dr. Jorge A. Garcia

Cleveland Clinic Taussig Cancer Institute, Ohio

See Curriculum
Jorge A. Garcia, MD., FACP, is an Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A Staff member of the Department of Solid Tumor Oncology and Urology at the Cleveland Clinic Taussig Cancer Institute and Glickman Urological Institute, Dr. Garcia’s work focuses on genitourinary malignancies. He is the current director of the advanced prostate cancer research program at the Cleveland Clinic.

Dr. Garcia earned his medical degree at the Colombian School of Medicine in Bogota, Colombia (South America). After completing a Cancer Biology Fellowship at Harvard Medical School, Dr. Garcia completed his training in Internal Medicine at the Albert Einstein College of Medicine in New York. Subsequently, Dr. Garcia was awarded a fellowship in hematology and oncology and Urologic Oncology at the University of California San Francisco.

Certified in Medical Oncology and Internal Medicine by the American Board of Internal Medicine, Dr. Garcia’s primary research at the Cleveland Clinic has been in prostate, kidney and bladder cancer, with special focus on developmental therapeutics and targeted therapy. Dr. Garcia’s has authored over 100 manuscripts and his research has been published in peer-reviewed journals that include New England Journal of Medicine, Clinical Cancer Research, Journal of Clinical Oncology, Journal of the National Cancer Institute, Lancet Oncology, Journal of Urology, Cancer and BJU International among others. He is a reviewer for several medical journals including, Clinical Cancer Research, Cancer, Urology, Annals of Oncology, Journal of Clinical Oncology, Clinical and Experimental Medicine and the BJU.

Dr. Garcia is a Fellow of the American College of Physicians and serves as a relevance reviewer for the American Board of Internal Medicine. He is also an editor for Urologic Oncology for the American Society of Clinical Oncology (ASCO) and currently serves as the Chair of the Scientific Protocol Review Committee at the Comprehensive Cancer Center at Case Western Reserve University. Dr. Garcia has also been listed among the best doctors in Cleveland and the United Stated every year since 2009.

Dr. Enrique Gallardo

Corporació Parc Taulí,
Sabadell

See Curriculum
Dr. Enrique Gallardo earned his degree in Medicine and Surgery from the University of Seville in 1990. Specialist in Medical Oncology since 1996, after their training at the Hospital General Vall d’Hebron in Barcelona between 1992 and 1995.

He was Attending at Oncology Department at Vall d’Hebron Hospital in 1996 and Clinical Trials Coordinator in the same department between 1996 and 1999, later to be Attending at Oncology Service at Terrassa Hospital in Barcelona until 2002. He is currently Senior Attending Physician at Oncology Department at Corporació Parc Taulí in Sabadell, Barcelona, and responsible for the Uro-Oncology Unit.

He is a member of the Spanish Group for treatment of Genito-Urinary Tumors (SOGUG) where is actively involved in Kidney Cancer and Bladder Cancer Working Groups. He is an active member of the SEOM (Spanish Society of Medical Oncology), ESMO (European Society of Medical Oncology), ASCO (American Society of Clinical Oncology), IASLC (International Association for the Study of Lung Cancer) and EORTC (European Organisation for the Research and Treatment of Cancer), Genito-Urinary Cancer Group.

He has participated as a researcher and designer in many clinical trials in various areas of oncology, especially in urological tumors, including phase I, II, II and IV trials. He has participated in the development of Prostate Cancer OncoGuide in Catalonia and SOGUG Kidney Cancer and Bladder Cancer Guides. He has published around 100 articles, book chapters and communications at national and international meetings.

His areas of expertise include the treatment of urological tumors (kidney, urothelial carcinomas, prostate and germ-cell tumors) and central nervous system neoplasms. He is also interested of other cancer-related areas, such as cancer-related thrombosis and supportive care.

Dr. Marc Simó

Hospital Universitari Vall d’Hebron,
Barcelona

See Curriculum

Last Name:  SIMO PERDIGÓ First Name: MARC Date of Birth: 14Feb1970Last Name:  SIMO PERDIGÓ First Name: MARC Date of Birth: 14Feb1970Study Site Affiliation:  (e.g., Principal Investigator, Subinvestigator, Coordinator) SubinvestigatorStudy Site Address: (Include institution name and country.) Hospital Universitari Vall d’HebronPº Vall d’Hebron 119-12908035 Barcelona, Spain
Professional Mailing Address of Investigator (if different from Study Site Address): (Include institution name and country.)
Hospital Universitari Vall d’HebronNuclear Medicine DepartmentPº Vall d’Hebron 119-12908035 Barcelona, Spain
Academic Qualifications including professional license (if applicable). Please enter most current date first.Specialist in Nuclear Medicine 2000 Hospital Universitari Vall d’hebron, SpainMedicine and Surgery Degree 1994 Barcelona University, Spain
Positions held in the last 5 years including current position:2000-Present  Physician Specialist in Nuclear Medicine Hospital Universitari Vall d’hebron, Spain2007-2014 Director Instituto Universtario QUIRON-DEXEUS, Spain2000-2007 Medical Doctor PET Unit CETIR Grup Medic, Spain

Brief Summary of Relevant Clinical Research Experience:
Participated in more than 30 clinical trials (phases II and III) in the last 5 years. ICH- GCP training.

Dr. David Olmos

Hosp. Univ. Virgen de la Victoria,
Málaga

See Curriculum

 

David Olmos trained as Medical Oncologist at the “Hosp. Univ. Virgen de la Victoria”, Málaga. He also received his PhD from the “Univ. de Málaga” and a Master degree in Biostatistics and Research Methodology from the UAB. In 2006, David joined The Royal Marsden Hospital-The Institute of Cancer Research, United Kingdom, to train as Clinician Scientist in the fields of Prostate Cancer and Drug Development. At the end 2012 he moved to Spanish National Cancer Research Centre (CNIO) to lead Prostate Cancer research, collaborating since 2013 with CIOCC and since 2015 with “IBIMA-HH.UU. de Málaga” in their Prostate Cancer clinical trials programmes. He also leads the PROCURE platform for biomakers research in CRPC.

 

David Olmos has published over 70 indexed paper with an H-index of 30 and has received several grants and awards including: an ESMO Research Fellowship (2006-2007), a SEOM Translational Research Fellowship (2009-2010), a GSK-AACR scholarship (2008), three ASCO merit awards (2008, 2009 and 2010) and three ESMO merit awards (2008, 2010 and 2012), “AECC – Beca de Retorno” 2012-2016”, “Juan Letona” Translational Medicine Research award 2013, Prostate Cancer Foundation YIA 2014, Astra-Zeneca YIA in Oncology 2015, and more recently a “Ramón y Cajal” fellowship from MINECO.

Dra. Himisha Beltran

Cornell University. Nueva York
EE.UU

See Curriculum
Dr. Himisha Beltran is a medical oncologist who specializes in caring for patients with genitourinary malignancies (prostate cancer, bladder cancer, germ cell tumor, kidney cancer). She joined the Division of Hematology and Medical Oncology as Assistant Professor of Medicine and Urology in 2011. Dr. Beltran received her undergraduate degree from the University of Oregon, her medical degree from New York Medical College and completed her residency at Hospital of the University of Pennsylvania and her fellowship in Hematology and Medical Oncology at The New York Hospital-Weill Cornell Medical College. Dr. Beltran is the recipient of numerous awards, including a Prostate Cancer Foundation Young Investigator Award and an AACR Women in Cancer Research Scholar Award. Dr. Beltran is actively involved in both laboratory-based and clinical research at Weill Cornell Medical College, and she serves as the liaison for several bench-to-bedside translational research efforts. Dr. Beltran is also directly involved in the development of a research program to study the molecular genetics of advanced prostate cancer, including an aggressive subtype called neuroendocrine (or anaplastic) prostate cancer. By studying the RNA and DNA of these tumors, she is learning how these cancers evolve, identifying molecular alterations to target with drugs, and developing clinical trials to bring new effective therapy to patients. Her goal is to help develop a cancer research program centered around personalized cancer care, which entails tailoring therapy for patients based on their cancer’s specific molecular profile. She is also involved in writing and leading several genitourinary clinical trials at Weill Cornell, and participates in national and international trials through the Alliance for Clinical Trials in Oncology Foundation (formerly CALGB) and National Cancer Institute (NCI).

Dr. Gerhardt Attard

The Institute of Cancer Research. Londres. UK

See Curriculum
Dr Attard is a Cancer Research UK Clinician Scientist and Team Leader at The Institute of Cancer Research and an Honorary Medical Oncology Consultant at the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 100 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. Dr Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. Dr Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.

Dra. Elena Castro

Centro Nacional de Investigaciones Oncológicas (CNIO).Madrid

See Curriculum
Elena Castro was born in Salamanca (Spain) in 1979. She received her MD from Universidad de Salamanca in 2003 and her PhD from the same university in 2010.
Elena specialized in Medical Oncology at Hospital Uiversitario de Salmanca, obtaining her license to practice in 2008. After completing her residency training, she moved to London where she worked for four years as clinical research fellow in cancer genetics and prostate cancer at the Insitute of Cancer Research & The Royal Marsden Hospital. With Prof R Eeles as her mentor, Elena focussed her research in populations with high risk of prostate cancer and the clinical and molecular characterization of prostate cancer tumours that harbor BRCA mutations.
Dr Castro moved back to Spain in January 2013 to the Prostate Cancer and GU tumours unit at the Spanish National Cancer Research Centre (CNIO) where she continues with her previous line of research.

Dr. Charles James Ryan

UCSF Medical Center. San Francisco. California. EE.UU.

See Curriculum
Charles J. Ryan, MD is Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.
His clinical practice focuses predominantly on advanced prostate cancer as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract.

Dra. Begoña Pérez Valderrama

Hospital Universitario Virgen del Rocío. Sevilla

See Curriculum
Begoña Pérez Valderrama es oncólogo médico en el H.U Virgen del Rocío de Sevilla desde el año 2006. Tutora MIR desde 2008 hasta 2012. Miembro del Comité Ético de Ensayos Clínicos local desde el año 2008 hasta 2012. Desde el año 2009 responsable de tumores genitourinarios y entre el año 2012 y 2016, responsable de Tumores del Sistema Nervioso Central. Miembro del Grupo Español de Tratamiento de Tumores Urológicos (SOGUG), del que forma parte como miembro de la Junta Directiva desde noviembre de 2015 como vocal de Proyectos e Investigación. Además, es miembro del Grupo Español de Investigación de Neuro-Oncología (GEINO), del Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI), del Grupo Español de Terapias Inmuno-biológicas en Cáncer (GETICA), de la Sociedad Andaluza de Oncología Médica y del Grupo Español de Oncología Médica (SEOM).

Dr. Albert Font Pous

Hospital Universitari Germans Trias i Pujol- ICO. Badalona

See Curriculum
Not available yet

Álvaro Pinto

Servicio de Oncología Médica, Hospital Universitario La Paz – IdiPAZ, Madrid

See Curriculum
– Licenciado en Medicina y Cirugía por la Universidad de Valladolid (2002)
– Médico Interno Residente de Oncología Médica en el Hospital Universitario La Paz, Madrid (2003-2007)
– Médico Adjunto del Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid (2007 – actualidad). Responsable de la atención a pacientes con tumores urológicos.
– Doctor en Medicina por la Universidad Autónoma de Madrid, calificado sobresaliente Cum Laude (2009)
– Investigador del Instituto de Investigación del Hospital La Paz (IdiPAZ), dentro del grupo de Oncología Traslacional
– Miembro de las siguientes sociedades científicas:

  • American Society of Clinical Oncology (ASCO)
  • European Society of Medical Oncology (ESMO)
  • Sociedad Española de Oncología Médica (SEOM)
  • Spanish Oncology Genitourinary Group (SOGUG). Asesor del Grupo de Cáncer de Vejiga.
  • Grupo Germinal

– Miembro de la Junta Directiva del Grupo Germinal (Grupo de Investigación en Tumores Germinales)
– Miembro de la Junta Directiva del Grupo Centro de Tumores Genitourinarios.
– Miembro del Grupo de Trabajo de Prevención del Cáncer y Diagnóstico Precoz de la SEOM
– Participación como investigador principal o investigador colaborador en más de 60 ensayos clínicos.
– Autor de artículos publicados en revistas de alto impacto del campo de la oncología (Journal of Clinical Oncology, Cancer Treatment Reviews, European Journal of Cancer, Cancer and Metastasis Reviews, Urologic Oncology, etc.)
– Autor de 16 capítulos en libros dentro del campo de la oncología
– Presentación de comunicaciones en congresos nacionales e internacionales (ASCO Annual Meeting, ESMO Annual Meeting. ASCO Genitourinary Cancer Symposium, etc.)

Dr. Miguel Ángel Climent

Instituto Valenciano de Oncología. Valencia

See Curriculum
Born in Valencia in 1963. Medicine studies in the Universidad of Valencia where he finished in 1987 with the licence in Medicine and Surgery with a extraordinary award. Fellowship in Medical Oncology in Hospital de la Santa Creu i Sant Pau of Barcelona from 1988 to1991. From 1992 he Works as a Medical Oncology specialist in the staff of Medical Oncology Service in Instituto Valenciano de Oncología Foundation. Since 2005 is Consultant and in charge of Genitourinary Tumours Section.
Doctor in Medicine in Universidad Autónoma of Barcelona in 1995. He has participated in clinical investigation and he has been Principal Investigator in the Insituto Valenciano de Oncología in more than 60 phase I, II and III Trials. He is author of many national and international papers. From 2008 to 2015 he has been member of the Directive Committee of SOGUG collaborative group and Chief of the Prostate Cancer Section of the Group.

Dr. Thomas Powles

Barts Cancer Institute. Londres.
UK

See Curriculum
Professor Thomas Powles is the Director of St Bartholomew’s Cancer Centre in London. His focus is on drug development in urology cancer with a particular focus on immune therapies. He lead a number of ongoing trials and has written over 200 papers in the field.

Dra. María Regina Gironés Sarrió

Hospital Lluís Alcanyís de Xàtiva. València

See Curriculum
Not available yet

Dr. Xavier García del Muro

Institut Català d’Oncologia.
Barcelona

See Curriculum
Is Medical Oncologist, Coordinator of the Unit of Genitourinary Tumors, Sarcoma and Melanoma of the Medical Oncology Department at the Institut Català d’Oncologia Bellvitge in Barcelona. He is Assistant Professor of Clinical Oncology at the University of Barcelona. He is member of the SOGUG Directive Board and coordinator of the renal cell cancer committee and was Chairman of The Spanish Group for Research on Sarcomas for 5 years. He has published more than 80 papers on genitourinary cancer and sarcoma in international scientific journals.

Dr. Jorge Aparicio

Hospital Universitari i Politècnic la Fe. València

See Curriculum
Licenciado en Medicina y Cirugía por la Universidad de Valencia (1987). Formación MIR entre 1988 y 1991 (H.U. y P. La Fe, Valencia). Oncólogo Médico (entre 1992 y 2009 como médico adjunto), Doctor en Medicina (1995) y desde 2010 hasta la actualidad Jefe de Sección de la Unidad de tumores digestivos y musculo-esqueléticos en el H.U. y P. La Fe (Valencia). Colaborador docente de la Facultad de Medicina (Universidad de Valencia).

Dedicado a la investigación clínica y traslacional. Principales campos de interés: tumores germinales testiculares y tumores del tracto digestivo, en particular cáncer colorrectal metastásico. Miembro de las siguientes sociedades médicas: Sociedad Española de Oncología Médica (SEOM, actualmente en su Junta Directiva), European Society of Medical Oncology (ESMO) y American Society of Clinical Oncology (ASCO). Miembro de los siguientes grupos cooperativos nacionales: Grupo Español para el Estudio y Tratamiento de los Tumores Digestivos (TTD), Grupo Español de Tumores Germinales (GG, expresidente, actualmente en su Junta Directiva) y Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD, vicepresidente actual). Investigador principal en 80 ensayos clínicos en Oncología Médica (37 de ellos internacionales).

Autor de 143 ponencias o conferencias en reuniones científicas o cursos de Oncología. Autor de 115 artículos publicados en revistas científicas nacionales y 91 en revistas internacionales, así como de 174 comunicaciones a congresos nacionales y 132 a congresos internacionales.

 

Dr. Ignacio Durán

Hospital Universitario Virgen del Rocío. Sevilla

See Curriculum
El Dr. Ignacio Durán trabaja en el Servicio de Oncología Médica del Hospital Universitario Virgen del Rocío de Sevilla. Fue coordinador de docencia y del programa de tumores genitourinarios del centro Integral Oncológico “Clara Campal” del Grupo Hospital de Madrid. Licenciado en Medicina y Cirugía por la Universidad de Salamanca y Doctor por la Universidad Complutense de Madrid. A lo largo de su carrera ha desarrollado estancias formativas en distintos centros investigadores nacionales e internacionales tales como la sede del CSIC de la Universidad de Salamanca, la Universidad Católica del Sacro Cuore de Roma (Italia), el “Centre Hospitalier Universitaire » de Nantes (Francia) y el “Memorial Sloan Kettering Cancer Center” de Nueva York (EE.UU).
Tras su formación clínica en el Hospital Clínico Universitario de Son Dureta (Palma de Mallorca), trabajó en el Servicio de Oncología Médica del Hospital Universitario Doce de Octubre (Madrid) y durante el trienio 2004-2007 en los departamentos de Desarrollo de Nuevos Fármacos y de Tumores Genitourinarios del “Princess Margaret Hospital” de Toronto (Ontario, Canadá).
Durante su estancia en Toronto completo un programa de Máster de docencia orientada a la medicina en la Universidad de Toronto. Es autor de importantes trabajos en diferentes ámbitos de la oncología médica publicados en destacadas revistas científicas. A lo largo de su carrera ha recibido entre otros galardones, el ASCO Foundation Merit Award, el Novartis Young Canadian Investigator Award y el University Health Network Outstanding Research Presentation Award.

Dr. Julio Lambea

Hospital Clínico Universitario Lozano Blesa. Zaragoza

See Curriculum
Nacido en Zaragoza el 22 de Agosto de 1971. Licenciado en Medicina en 1995 en la Universidad de Zaragoza. Doctor en Medicina en Enero 2006 por la Universidad de Zaragoza, tesis basada en líneas celulares de carcinoma renal. Tras estancia de 3 meses en el Hillmann Cancer Center de Pittsburgh (EEUU) en el área de Inmunología tumoral. Experto Universitario en Investigación Oncológica, Análisis de estudios y gestión clínica. Especialista en Oncología Médica y Especialista en Hematología y Hemoterapia. Áreas de máximo interés oncológico son el carcinoma renal y los tumores de cabeza y cuello y de tiroides.
Actividad asistencial en el Servicio de Oncología Médica del Hospital Clínico Lozano Blesa de Zaragoza. Miembro del Instituto de Nanociencia de Aragón. Profesor Asociado del Departamento de Medicina de la Universidad de Zaragoza. Tutor de Residentes de Oncología Médica. Presidente del Comité Técnico Provincial de la AECC.

Dr. Pablo Maroto

Hospital de la Santa Creu i Santa Pau. Barcelona

See Curriculum
Dr. Maroto is a medical oncologist working in the Sant Pau Hospital of Barcelona, Spain since 1999. From his position, Dr. Maroto has been actively working in the uro-oncology arena participating in more than 30 international clinical trials as principal investigator. He is member of different collaborative groups, among them the Spanish Oncology Genito-Urinary Group (SOGUG) where he has collaborated in the elaboration of Spanish Guidelines for the management of prostate, kidney and bladder cancer. Besides, he presently is the Chairman of the Germ Cell Cancer Group, the Spanish collaborative group for the treatment of Germ Cell cancer.

Dr. Neeraj Agarwal

Huntsman Cancer Institue, University of Utah. Salt Lake City. Utah. EE.UU.

See Curriculum
Neeraj Agarwal, MD, is an Associate Professor in the Division of Oncology, Department of Medicine, at the University of Utah School of Medicine. He is the Director of the Genitourinary Oncology Program in the Oncology Division, the Co-leader of the Urologic Oncology Multidisciplinary Program and the Associate Director of Clinical Trials (solid tumors) at the Huntsman Cancer Institute (HCI).
As a specialist in adult hematology and oncology, Dr. Agarwal cares for patients with all types of cancer and specializes in genitourinary malignancies (cancers of the prostate, kidney, bladder and testes).
Dr. Agarwal is a member of several professional societies, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the Southwest Oncology Group (SWOG). After receiving his MD degree from All India Institute of Medical Sciences in New Delhi, India, Dr. Agarwal completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa. He then completed a hematology-oncology fellowship at HCI and the University of Utah School of Medicine.

Dr. Jose Luis Pérez Gracia

Clinica Universidad de Navarra. Pamplona.

See Curriculum

Current positions:

  • Associate Professor of Medicine at the University of Navarra (unav.es)
  • Senior consultant at department of Oncology Clinica Universidad de Navarra (cun.es).
  • Head of the Clinical Research Unit. Clinica Universidad de Navarra (cun.es)

Education and training.

  • Medical degree: Universidad Autónoma de Madrid (1988-1994)
  • Residency in Medical Oncology at Hospital Universitario 12 de Octubre, Madrid (1994-1998).
  • PhD at Universidad Complutense de Madrid (2001).

Professional experience.

Jose Luis Perez-Gracia serves as Associate Professor of Medicine at the University of Navarra. He is the head of the Clinical Research and Genitourinary Tumors Units at the Department of Oncology (University Clinic of Navarra). He is dedicated to Biomarker research and Cancer Immunotherapy.

He has wide experience in cancer immunotherapy and has participated in several phase I, II and III studies since 2012, mainly in urological cancer and combination immunotherapy.

He has coauthored over 100 manuscripts in international peer-reviewed journals, over 90 communications to oncology international meetings and 14 books. He has been principal investigator in 9 research projects -including 2 multi-institutional projects funded by the European Union- and more than 90 clinical trials. He belonged to the Executive Board of the Spanish Group for Research in Urologic Tumors (www.sogug.es) from 2009 to 2015. He has been peer-reviewer of 12 international journals and is Academic Editor of PlosOne.

Dr. José Ángel Arranz

Hospital Universitario Gregorio Marañón

See Curriculum
Licenciado en Medicina y Cirugía (Universidad de Valladolid, 1985).Especialista en Oncología Médica (Hospital General Universitario Gregorio Marañón, 1990).
Miembro del Comité de Expertos en Tumores Urológicos de la Consejería de Salud de la Comunidad Autónoma de Madrid (1993).
Diplomatura en Informática y Estadística (Universidad Autónoma de Barcelona, 1994).
Jefe de Sección del Servicio de Oncología Médica del Hospital General Universitario Gregorio Marañón (desde 2007 hasta la actualidad), y responsable de la “Unidad de Tumores Urológicos y Ginecológicos” en dicho centro.

Dra. Aránzazu González del Alba

Hospital Universitario Son Espases. Palma de Mallorca

See Curriculum
Dr. Aránzazu González del Alba Baamonde holds a Degree in Medicine and Surgery from Madrid Autonomous University (1993).
She completed her training in Clinical Oncology in Son Dureta University Hospital (Palma de Mallorca, 1994-1997) and holds a Master in Molecular Oncology: Molecular bases of Cancer. Molecular Pathology Program of the National Oncological Research Centre (CNIO), recognized by the European School of Oncology (2007-2009).
She is a staff physician of the Department of Clinical Oncology of Son Espases Universitary Hospital and since 2002 she has directed the Unit of Urological and Gynecological tumors.
Since 2009 she forms part of the Steering Committee of the Spanish Oncology Genitourinary Group (SOGUG), coordinating the Teaching Commission.

Passatge Batlló, 15
Barcelona

T. +34 93 451 17 24
F. 93 451 43 66

info@tacticsmd.net


NH COLLECTION MADRID EUROBUILDING
Padre Damián, 23
Madrid
T. +34 91 353 73 00